16 September 2026 editorial review · Item
CELZ-201 perinatal tissue-derived cell therapy: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: CELZ-201's current randomized Phase 1/2a trial plans 18 recent-onset adults aged 18–35 and pancreatic-artery infusion. No posted results. A regenerative mechanism and safety endpoints do not prove regeneration or safety.
- Registry NCT05626712: RECRUITING; updated 2026-02-19; enrollment 18 (ESTIMATED); primary completion 2027-01-31 (ESTIMATED); results not posted in retrieved record.
- Programme/sponsor/conference source boundary: CELZ-201 for the Treatment of New Onset Type 1 Diabetes in Adults (manufacturer); CELZ-201 Clinical Trial (manufacturer).